Understanding these pathways becomes critical as it is known that anti-cancer therapeutics including those that target epidermal growth factor receptor (anti-ERBB agents) family5,6 leads to cardiac dilation of the otherwise healthy hearts bypassing the adaptive hypertrophic response7. Here, EGFR is linked to cancer.